CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 821 - 830 of 842
Study Number Lead Group Study Title CIRB Study Status
10075 ETCTN A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Available to Open
10070 ETCTN Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10067 ETCTN A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy Adult CIRB - Early Phase Emphasis Available to Open
10066 ETCTN A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Adult CIRB - Early Phase Emphasis Available to Open
10061 ETCTN A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10058 ETCTN A Phase I Study of talimogene laheparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum Adult CIRB - Early Phase Emphasis Available to Open
10056 ETCTN A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Adult CIRB - Early Phase Emphasis Available to Open
10050 ETCTN A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutations Adult CIRB - Early Phase Emphasis Completed
10042 ETCTN A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases Adult CIRB - Early Phase Emphasis Available to Open
10031 ETCTN A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer Adult CIRB - Early Phase Emphasis Available to Open
Displaying 821 - 830 of 842